Annovis Bio Fails NYSE Listing Standards Due to Low Market Capitalization

Annovis Bio, Inc. received notice from the New York Stock Exchange that it is no longer compliant with continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual. This was due to the company’s average market capitalization over a 30 trading-day period being less than $50 million, and its stockholders’ equity being less than $50 million. The company has been given 45 days to submit a plan to bring itself into conformity within nine months.

Regulatory changes are impacting the market listing status of companies on the New York Stock Exchange, which operates under the oversight of the Securities and Exchange Commission. The failure to meet these standards affects the company's public trading status.

Regulatory changes are impacting the market listing status of companies on the New York Stock Exchange, involving the Securities and Exchange Commission.